ozempic vs semaglutide vs tirzepatide Tirzepatide: Choose the Right Weight loss Treatment Semaglutide vs Tirzepatide: Research Comparison

Meet our doctors Last reviewed: 19 Jun 2026 Sources Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients (2020) NIH [accessed 27 January 2026] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial (2023) The Lancet [accessed 27 January 2026] How to use Mounjaro (2023) Mounjaro [accessed 27 January 2026] Lillys SURMONT-2 results published in The Lancet show tirzepatide achieve a mean weight reduction of 15.7% at the highest dose (15mg) in adults with obesity or overweight and type 2 diabetes (2023) Lillys INVESTORS [accessed 27 January 2026] MHRA authorised diabetes drug Mounjaro (tirzepatide) for weight management and weight loss (2023) GOV.UK

The most common adverse event reported by patients was nausea and vomiting, which occurred among 26.3% of the study group

therefore, it is not yet available as a prescription medicine

Laboratory testing provides objective confirmation